AUTHOR INDEX

Abebe, W. Herbal medication: potential for adverse interactions with analgesic drugs, 391
Akhondzadeh, S., Mojtahedzadeh, V., Mirsepassi, G.-R., Moin, M., Amini-Nooshabadi, H. & Kamalipour, A. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia, 453
Al Balushi, K. *see* Hanssens, Y.
Al Hashar, A. *see* Hanssens, Y.
Al-Zakwani, I. *see* Hanssens, Y.
Amini-Nooshabadi, H. *see* Akhondzadeh, S.
Anderson, S. *see* Whitefield, M.
Armstrong, D. *see* Ashworth, M.
Arsène, M., Favetta, P., Favier, B. & Bureau, J. Comparison of ceftazidime degradation in glass bottles and plastic bags under various conditions, 205
Ashworth, M., Armstrong, D., Lloyd, D. & Colwill, S. The effects on GP prescribing of joining a commissioning group, 221
Ashworth, M., Golding, S. & Majeed, A. Prescribing indicators and their use by primary care groups to influence prescribing, 197
Ashworth, M. Re: GPs' views on computerized drug interaction alerts, 311
Avery, A.J. *see* Magnus, D.

Babalola, C.P., Iwheye, G.B. & Olaniyi, A.A. Effect of proguanil interaction on bioavailability of cloxacillin, 461
Belal, F. *see* Walash, M.I.
Bertilsson, L. *see* Ding, B.
Bevanda, M. *see* Rosandić, M.
Björnsdóttir, I. & Hansen, E.H. Ethical dilemmas in antibiotic prescribing: analysis of everyday practice, 431
Boehm, B.-O. *see* Uhl, A.
Bonnier, P. *see* Monjanel-Mouterde, S.
Borel-Derlon, A. *see* Divanon, F.
Borenstein, M.R. *see* Tao, Q.
Bouvy, M.L., Buurma, H. & Egberts, T.C.G. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention, 107
Bureau, J. *see* Arsène, M.
Burke, V. *see* Millar, J.A.
Buurma, H. *see* Bouvy, M.L.

Chan, C.S.Y., Fabb, W.E. & Hazlett, C.B. Validation of an instrument to assess patient attitudes towards prescribing of pharmaceuticals by doctors:, 249
Chan, C.S.Y. *see* Wun, Y.T.
Chen, A. *see* Chow, A.T.
Chiba, M. *see* Konishi, H.
Chien, S.-C., Rogge, M.C., Williams, R.R., Natarajan, J., Wong, F. & Chow, A.T. Absence of a pharmacokinetic interaction between digoxin and levofloxacin, 7
Chow, A.T., Chen, A., Lattime, H., Morgan, N., Wong, F., Fowler, C. & Williams, R.R. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses, 143
Chow, A.T. *see* Chien, S.-C.
Chowdhary, S. *see* Routledge, H.C.
Ciaccia, L.M. *see* Schock Citver, A.
Ciccolini, J. *see* Monjanel-Mouterde, S.
Codd, E.E. *see* Tao, Q.
Colwill, S. *see* Ashworth, M.
Coogan, T.P. *see* Tao, Q.
Cottrell, N. *see* Green, B.
Cunningham, F. *see* Ren, X.S.
Czock, D. *see* Uhl, A.

D'Emden, M. *see* Green, B.
Deleu, D. *see* Hanssens, Y.
Demoré, B., Vigneron, J., Perrin, A., Hoffman, M.A. & Hoffman, M. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous etoposide solution, 139
Desai-Krieger, D. *see* Tao, Q.
Dey, C.S. *see* Jayanarayan, K.G.
Dickinson, J.A. *see* Wun, Y.T.
Ding, B., Bertilsson, L. & Wahlestedt, C. The single nucleotide polymorphism T1128C in the signal peptide of neuropeptide Y (NPY) was not identified in a Korean population, 211
Divanon, F., Hecquard, C. & Borel-Derlon, A. Experience with use of recombinant activated factor VII, 133
Donahue, S. *see* Reddy, P.
Duffull, S. *see* Green, B.
Durand, A. *see* Monjanel-Mouterde, S.

Eastaugh, J. *see* Freemantle, N.
Echizen, H. *see* Kadota, K.
Egberts, T.C.G. *see* Bouvy, M.L.
Eid, M. *see* Walash, M.I.

Fabb, W.E. *see* Chan, C.S.Y.
Fališevac, V. *see* Rosandić, M.
Favetta, P. *see* Arsène, M.
Favier, B. *see* Arsène, M.
Feret, B.M. *see* Reddy, P.
Ferner, R.E. *see* Langford, N.J.
Forrest, A. *see* Miyazawa, Y.
Fowler, C. *see* Chow, A.T.
Freemantle, N. & Eastaugh, J. Using effectiveness studies for prescribing research, part 1, 383
Freemantle, N. & Eastaugh, J. Using effectiveness studies for prescribing research, part 2, 469
Fujii, A. *see* Kaneda, Y.

Gaunt, M.J. *see* Maiorini, A.F.
Ghayoumi, A. *see* Rouini, M.
Golding, S. *see* Ashworth, M.
Green, B., Duffull, S., Cottrell, N. & D'Emden, M. Myocardial infarction and type II diabetes – preferential treatment for high risk patients?, 371

Hadjaj, D. *see* Monjanel-Mouterde, S.
Hamada, M. *see* Hara, Y.

© 2002 Blackwell Science Ltd

Hamed, A. *see* Ren, X.S.
Hamidi, M. *see* Rouini, M.
Hannaford, P.C. *see* Simpson, J.A.
Hansen, E.H. *see* Björnsdóttir, I.
Hansen, E.H. *see* Trap, B.
Hanssens, Y., Deleu, D., Al Balushi, K., Al Hashar, A. & Al-Zakwani, I. Drug utilization pattern of antiepileptic drugs: a pharmacoepidemiologic study in Oman, 357
Hara, Y., Hamada, M., Shigematsu, Y., Ohtsuka, T. & Hiwada, K. Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients:, 267
Hazlett, C.B. *see* Chan, C.S.Y.
Hecquard, C. *see* Divanon, F.
Hefnawy, M. *see* Walash, M.I.
Hino, B. *see* Teshima, D.
Hirsch, G.M. *see* Thompson, A.E.
Hiwada, K. *see* Hara, Y.
Hoffman, M. *see* Demoré, B.
Hoffman, M.A. *see* Demoré, B.
Hone, S. *see* Walshe, P.
Huang, Y.H. *see* Ren, X.S.
Hughes, L., Whittlesea, C. & Luscombe, D. Patients' knowledge and perceptions of the side-effects of OTC medication:, 243

Ibrahim, F. *see* Walash, M.I.
Ismailpour, A. *see* Rouini, M.
Ito, Y. *see* Miyazawa, Y.
Itoh, Y. *see* Sendo, T.
Itoh, Y. *see* Teshima, D.
Iwheye, G.B. *see* Babalola, C.P.

Jacobsen, T.M. *see* Maiorini, A.F.
Jayanarayan, K.G. & Dey, C.S. Microtubules: dynamics, drug interaction and drug resistance in *Leishmania*, 313
Jones, B.W., Moore, D.J., Robinson, S.M. & Song, F. A systematic review of tegaserod for the treatment of irritable bowel syndrome, 343

Kadota, K., Kamata, K., Kobayashi, Y., Kagaya, H., Shimada, S., Yoshimoto-Furuie, K. & Echizen, H. Nomogram for individualizing supplementary iron doses during erythropoietin therapy in haemodialysis patients, 111
Kagaya, H. *see* Kadota, K.
Kamalipour, A. *see* Akhondzadeh, S.
Kamata, K. *see* Kadota, K.
Kamimura, H. *see* Miyazawa, Y.
Kaneda, Y. & Fujii, A. Gynecomastia with sulpiride, 75
Kang, S.-S. *see* Park, H.-M.
Kazis, L.E. *see* Ren, X.S.
Keller, F. *see* Uhl, A.
Kendall, M.J. & Nuttall, S.L. The heart protection study: statins for all those at risk?, 1
Kendall, M.J. *see* Landray, M.J.
Kephart, G.C. *see* Morningstar, B.A.
Kim, O.-N. *see* Park, H.-M.
Kobayashi, Y. *see* Kadota, K.
Koida, M. *see* Konishi, H.
Konishi, H., Shimizu, S., Chiba, M., Minouchi, T., Koida, M. & Yamaji, A. Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyperbolic model based on creatinine clearance:, 257
Korać, B. *see* Rosandić, M.
Kulicki, L. *see* Reddy, P.

Landray, M.J., Toescu, V. & Kendall, M.J. The cardioprotective role of β-blockers in patients with diabetes mellitus:, 233
Langford, N.J., Martin, U., Ruprah, M. & Ferner, R.E. Alternative venlafaxine kinetics in overdose, 465
Langford, N.J. Aspirin and Reye's syndrome: is the response appropriate?, 157
Larrivee-Elkins, C. *see* Öster Svedberg, K.
Lattime, H. *see* Chow, A.T.
Lee, A. *see* Ren, X.S.
Lee, A.F. *see* Ren, X.S.
Lee, S.-B. *see* Park, H.-M.
Lee, Y.-B. *see* Park, H.-M.
Lejeune, C. *see* Monjanel-Mouterde, S.
Li Wan Po, A. Digoxin–drug interactions study design and generalizability, 5
Liao, S. *see* Tao, Q.
Llopis, P. *see* Sánchez-Alcaraz, A.
Lloyd, D. *see* Ashworth, M.
López, E. *see* Sánchez-Alcaraz, A.
Luscombe, D. *see* Hughes, L.

McKay, A.E. *see* Maiorini, A.F.
McKenzie, J. *see* Öster Svedberg, K.
Magnus, D., Rodgers, S. & Avery, A.J. GPs' views on computerized drug interaction alerts: questionnaire survey, 377
Maiorini, A.F., Gaunt, M.J., Jacobsen, T.M., McKay, A.E., Waldman, L.D. & Raffa, R.B. Potential novel targets for Alzheimer pharmacotherapy: I. Secretases, 169
Majeed, A. *see* Ashworth, M.
Makino, K. *see* Sendo, T.
Mant, J. & Vessey, M. Using case-control studies for prescribing research, 67
Martin, U. *see* Langford, N.J.
Merite, N. *see* Monjanel-Mouterde, S.
Mertz, A. *see* Uhl, A.
Millar, J.A. & Burke, V. Relationship between sample size and the definition of equivalence in non-inferiority drug studies, 329
Miller, D.R. *see* Ren, X.S.
Minouchi, T. *see* Konishi, H.
Mirsepassi, G.-R. *see* Akhondzadeh, S.
Mishima, K. *see* Sendo, T.
Miyazawa, Y., Starkey, L.P., Forrest, A., Schentag, J.J., Kamimura, H., Swarz, H. & Ito, Y. Effects of the concomitant administration of tamsulosin (0·8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin®) in normal healthy subjects a placebo-controlled evaluation, 13
Moin, M. *see* Akhondzadeh, S.
Mojtahedzadeh, V. *see* Akhondzadeh, S.

Mokbel, K. *see* Singh-Ranger, G.
Monjanel-Mouterde, S., Lejeune, C., Ciccolini, J., Merite, N., Hadjaj, D., Bonnier, P., Piana, P. & Durand, A. Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer, 189
Moore, D.J. *see* Jones, B.W.
Morgan, N. *see* Chow, A.T.
Morningstar, B.A., Sketris, I.S., Kephart, G.C. & Sclar, D.A. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada, 213

Natarajan, J. *see* Chien, S.-C.
Nguyen, H.A. *see* Olsson, E.
Nuttall, S.L. *see* Kendall, M.J.

O'Kane, C.J.A. *see* Whitefield, M.
Ohtsuka, T. *see* Hara, Y.
Oishi, R. *see* Sendo, T.
Oishi, R. *see* Teshima, D.
Olaniyi, A.A. *see* Babalola, C.P.
Olsson, E., Tuyet, L.T.N., Nguyen, H.A. & Stålsby Lundborg, C. Health professionals' and consumers' views on the role of the pharmacy personnel and the pharmacy service in Hanoi, Vietnam – a qualitative study:, 273
Öster Svedberg, K., McKenzie, J. & Larrivee-Elkins, C. Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine, 39

Park, H.-M., Kang, S.-S., Lee, Y.-B., Shin, D.-J., Kim, O.-N., Lee, S.-B. & Yim, D.-S. Population pharmacokinetics of intravenous valproic acid in Korean patients, 419
Pearson, G.J. *see* Thompson, A.E.
Perrin, A. *see* Demoré, B.
Piana, P. *see* Monjanel-Mouterde, S.
Pilaš, V. *see* Rosandić, M.

Quercia, R.A. *see* Reddy, P.
Quintana, M^{a}.B. *see* Sánchez-Alcaraz, A.

Raffa, R.B. *see* Maiorini, A.F.
Raffa, R.B. *see* Schock Citver, A.
Raffa, R.B. *see* Tao, Q.
Ramesh, M. & Roberts, G. Use of night-time benzodiazepines in an elderly inpatient population, 93
Rane, A. *see* Xie, H.-J.
Reddy, P., Feret, B.M., Kulicki, L., Donahue, S. & Quercia, R.A. Cost analysis of fentanyl and remifentanil in coronary artery bypass graft surgery without cardiopulmonary bypass, 127
Ren, X.S., Kazis, L.E., Lee, A., Zhang, H. & Miller, D.R. Identifying patient and physician characteristics that affect compliance with antihypertensive medications, 47
Ren, X.S., Kazis, L.E., Lee, A.F., Hamed, A., Huang, Y.H., Cunningham, F. & Miller, D.R. Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia, 441
Roberts, G. *see* Ramesh, M.
Robinson, S.M. *see* Jones, B.W.
Rodgers, S. *see* Magnus, D.
Rodríguez, I. *see* Sánchez-Alcaraz, A.
Rogge, M.C. *see* Chien, S.-C.
Rosandić, M., Pilaš, V., Bevanda, M., Fališevac, V. & Korać, B. Quantification of *Helicobacter pylori* resistance in functional and organic dyspepsia, 353
Ross-Degnan, D. *see* Wagner, A.K.
Rouini, M., Hamidi, M., Ghayoumi, A. & Ismailpour, A. Relationship of serum ACE inhibition to oral dose of enalapril in normotensive volunteers, 121
Routledge, H.C., Chowdhary, S. & Townend, J.N. Heart rate variability – a therapeutic target?, 85
Rowley, H. *see* Walshe, P.
Ruprah, M. *see* Langford, N.J.

Sánchez-Alcaraz, A., Quintana, M^{a}.B., López, E., Rodríguez, I. & Llopis, P. Effect of vigabatrin on the pharmacokinetics of carbamazepine, 427
Sandberg, M. *see* Xie, H.-J.
Schentag, J.J. *see* Miyazawa, Y.
Schock Citver, A., Shields, A.M., Ciaccia, L.M., Schulingkamp, R.J. & Raffa, R.B. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia III. Retinoids, 161
Schulingkamp, R.J. *see* Schock Citver, A.
Sclar, D.A. *see* Morningstar, B.A.
Sendo, T., Teshima, D., Makino, K., Mishima, K., Itoh, Y. & Oishi, R. Application of dynamic laser scattering to the quality control of injectable drugs polymer formation in ampicillin solution, 79
Shields, A.M. *see* Schock Citver, A.
Shigematsu, Y. *see* Hara, Y.
Shimada, S. *see* Kadota, K.
Shimizu, S. *see* Konishi, H.
Shin, D.-J. *see* Park, H.-M.
Simpson, J.A. & Hannaford, P.C. The contribution of cohort studies to prescribing research, 151
Singh-Ranger, G. & Mokbel, K. Current concepts in cyclooxygenase inhibition in breast cancer, 321
Sketris, I.S. *see* Morningstar, B.A.
Song, F. *see* Jones, B.W.
Soumerai, S.B. *see* Wagner, A.K.
Stålsby Lundborg, C. *see* Olsson, E.
Starkey, L.P. *see* Miyazawa, Y.
Stone, D.J. *see* Tao, Q.
Swarz, H. *see* Miyazawa, Y.

Tao, Q., Stone, D.J., Borenstein, M.R., Codd, E.E., Coogan, T.P., Desai-Krieger, D., Liao, S. & Raffa, R.B. Differential tramadol and *O*-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally, 99
Teshima, D., Hino, B., Itoh, Y. & Oishi, R. Simple and simultaneous determination of sulphapyridine and acetylsulphapyridine in human serum by column-switching high-performance liquid chromatography, 403
Teshima, D. *see* Sendo, T.
Thompson, A.E., Hirsch, G.M. & Pearson, G.J. Assessment of new onset postcoronary artery bypass surgery atrial fibrillation current practice pattern review and the development of treatment guidelines, 21
Timon, C. *see* Walshe, P.
Toescu, V. *see* Landray, M.J.
Townend, J.N. *see* Routledge, H.C.

Trap, B. & Hansen, E.H. Treatment of upper respiratory tract infections – a comparative study of dispensing and non-dispensing doctors:, 289
Tuyet, L.T.N. *see* Olsson, E.

Uhl, A., Czock, D., Boehm, B.-O., Zellner, D., Mertz, A. & Keller, F. Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions:, 281

Vessey, M. *see* Mant, J.
Vigneron, J. *see* Demoré, B.

Wagner, A.K., Soumerai, S.B., Zhang, F. & Ross-Degnan, D. Segmented regression analysis of interrupted time series studies in medication use research:, 299
Wahlestedt, C. *see* Ding, B.
Walash, M.I., Belal, F., Ibrahim, F., Hefnawy, M. & Eid, M. Voltammetric determination of nitrosocimetidine in simulated gastric juice, 365
Waldman, L.D. *see* Maiorini, A.F.
Walshe, P., Rowley, H., Hone, S. & Timon, C. Co-phenylcaine as an alternative to Brompton's solution in rigid nasendoscopy: a pilot study, 185
Whelan, A.M. Development of a Canadian family medicine pharmacy practice experience programme, 335
Whitefield, M., O'Kane, C.J.A. & Anderson, S. Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study, 409
Whittlesea, C. *see* Hughes, L.
Williams, R.R. *see* Chien, S.-C.
Williams, R.R. *see* Chow, A.T.
Wong, F. *see* Chien, S.-C.
Wong, F. *see* Chow, A.T.
Wun, Y.T., Chan, C.S.Y. & Dickinson, J.A. Determinants of physicians' attitude towards prescribing, 57

Xie, H.-J., Yasar, Ü., Sandberg, M. & Rane, A. Paeoniae Radix, a traditional Chinese medicine, and CYP2C9 activity, 229

Yamaji, A. *see* Konishi, H.
Yasar, Ü. *see* Xie, H.-J.
Yim, D.-S. *see* Park, H.-M.
Yoshimoto-Furuie, K. *see* Kadota, K.

Zellner, D. *see* Uhl, A.
Zhang, F. *see* Wagner, A.K.
Zhang, H. *see* Ren, X.S.

KEYWORD INDEX

ACE inhibitors, 85
Acetaminophen, 391
Acetylsulphapyridine, 403
Active metabolite, 99
Adverse drug interactions, 391
Adverse drug reactions, 243
Adverse effects, 403
Alzheimer's disease, 169
Ampicillin sodium, 79
Amyloid precursor protein, 169
Amyloid β-peptide, 169
Anaesthesia, 185
Analgesic drugs, 391
Angiotensin converting enzyme activity, 121
Angiotensin converting enzyme inhibitors, 121
Angiotensin II receptor antagonist, 267
Angiotensin-converting enzyme inhibitor, 267
Antibiotic resistance, 353
Antibiotic use, 289
Antibiotics, 431
Anti-epileptic drugs, 357
Anti-hypertensive drugs, 121
Antihypertensive medications, 47
Antimalarial, 461
Antimicrotubule agents, 313
Assay, 79
Atrial fibrillation, 21
Attitude, 57
Atypical antipsychotics, 441
Autonomic nervous system, 85

Baroreflex sensitivity, 85
Bayesian estimation, 189
Benzodiazepines, 93
Beta-blockers, 85
Bioavailability, 461
β-blocker, 233, 267
Blood glucose, 371
Brain, 99
Breast cancer, 321

Carbamazepine, 427
Cardiac surgery, 127
Cardioprotection, 233
Case-control studies, 67
Ceftazidime, 205
Cimetidine, 365
Clinical practice, 383
Clinical trials, 329
Cloxacillin, 461
Cocaine, 185
Cohort studies, 151
Column-switching, 403
Compliance, 47
Complicated skin infections, 143
Complicated skin-structure infections, 143
Computers, 377
Congestive heart failure, 257
Content analysis, 273
Controlled trial, 221
Co-phenylcaine, 185
Coronary artery bypass, 21
Coronary heart disease, 233
Costs, 127
Creatinine clearance, 257
Cyclooxygenase-1 (COX-1), 321
Cyclooxygenase-2 (COX-2), 321
Cyclooxyge-nase inhibitors, 321
CYP2C9, 229
CYP2D6, 465

Degradation, 205
Diabetes, 213
Diabetes mellitus, 233, 371
Diazoxide, 453
Diethylhexyl phthalate (DEHP), 139
Digoxin, 7, 13
Dilated cardiomyopathy, 267
Dispensing doctors, 289
Dosage, 289
Dose–effect relationship, 121
Dose–response, 281
Dosing, 281
Drug information, 335
Drug interaction alerts, 377
Drug resistance, 313
Drug utilization, 357
Drug–drug interaction, 461
Dyspepsia, 353

Elderly patients, 93
Enalapril, 121
Epilepsy, 357
Estradiol, 75
Etoposide, 139

Family medicine, 335
Family practice, 377
Fentanyl, 127
Folinic acid rescue, 189
Functional, 353

Gas chromatography, 99
General family practice, 249
General practice, 377, 431
Glass, 205
Gonadotropins, 75
Gynecomastia, 75

Haemodialysis, 111
Health policy evaluation, 299
Heart rate variability, 85
Helicobacter pylori, 353
Herbal supplements, 391
Hierarchical design, 469
Hormone replacement therapy, 67
HPLC, 139
HTF 919, 343
Hyperbolic prediction model, 257
Hypertension, 47

Ibuprofen, 409
Iceland, 431
Immunosuppression, 281
Implementation, 383
Implementation study, 469
Infection, 353
Initiation, 441
Insulin, 371
Interactions, 427
Interrupted time series design, 299
Intervention, 107
Iron supplement nomogram, 111
Irritable bowel syndrome, 343

Knowledge, 243
Korean, 211

Laxatives, 107
Leishmania, 313
Levofloxacin, 7, 143
Longitudinal analysis, 299
Losartan, 229

Medication adherence, 213
Medication use research, 299
Metabolism, 465
Methotrexate, 189
Metronidazole, 353
Microtubules, 313
Mixed effect modelling, 419
Mononitrosocimetidine (MNCM), 365
Myocardial infarction, 371

Natriuretic peptides, 267
Neuropeptide Y, 211
Nitrosocimetidine (NCM), 365
Non-inferiority, 329
Non-steroidal anti-inflammatory drugs, 409
Nose, 185
NSAIDs, 321, 391

Obligations, 431
Opioids, 107, 391
Oral, 409
Oral antihyperglycaemic drugs, 213
Organic, 353

© 2002 Blackwell Science Ltd

OTC medicines, 243
Overdose, 465

Paeoniae Radix, 229
Patient and physician characteristics, 47
Patient attitude, 249
Patient characteristics, 441
Pharmacist, 107
Pharmacodynamics, 281
Pharmacoepidemiology, 357
Pharmacokinetic interaction, 13
Pharmacokinetics, 7, 143, 189, 419, 465
Pharmaco-therapy, 357
Pharmacy, 273
Pharmacy practice experience programme, 335
Pharmacy practice research, 107
Pharmacy services, 335
Phenomenography, 273
Phenytoin, 229
Placebo-controlled study, 13
Plasma, 99
Plasma concentrations, 427
Polymer formation, 79
Polypropylene, 205
Polyvinyl chloride (PVC) bags, 139
Polyvinyl chloride, 205
Population, 419
Population-based study, 213
Posology, 281
Potassium channels, 453
Practice guidelines, 21
Prescribing, 289
Prescribing adviser, 221
Prescribing change, 221
Prescribing indicators, 197
Prescribing information systems, 1, 5, 7, 47, 57, 75
Prescribing research, 151
Prescription, 57
Prescription behaviour, 249
Prescription patterns, 441
Presenilin, 169
Primary care groups, 197
Primary care, 57, 221
Prioritization, 431
Proguanil, 461
Prolactin, 75
Pyridine, 205

Qualitative, 273
Qualitative methods, 431
Quality assurance, 21
Quasi-experimental design, 299
Questionnaire survey, 377
Questionnaire validation, 249

Randomized controlled trials, 383
RAR, 161
Remifentanil, 127
Respiratory infections, 289
Retinoid receptors, 161
Retinoids, 161
r-HuEPO, 111
Role, 273
RXR, 161

Safety, 13
Schizophrenia, 161, 441, 453
Secretase, 169
Segmented regression analysis, 299
Serum digoxin concentration, 257
Side effects, 243
Simulated gastric juice (SGJ), 365
Single nucleotide polymorphism, 211
Sleep, 93
Soft tissue injury, 409
Sorption, 205
Stability, 79
Statistical analysis plan, 469
Statistical testing, 329
Study design, 469
Submicron particle analysis, 79
Sudden death, 85, 233
Sulphapyridine, 403
Sulpiride, 75
Switching, 441
Systematic review, 343

Tamsulosin, 13
Tegaserod, 343
Temazepam, 93
Testosterone, 75
Therapeutic equivalence, 329
Thoracic surgery, 21
Thromboembolism, 67
Topical, 409
Tramadol, 99
Treatment guidelines, 21

Valproic acid, 419
Venlafaxine, 465
Vigabatrine, 427
Voltammetry, 365